Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration.

Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, Selley DE.

Mol Pharmacol. 2006 Sep;70(3):986-96. Epub 2006 Jun 7.

PMID:
16760363
2.

Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.

Selley DE, Rorrer WK, Breivogel CS, Zimmer AM, Zimmer A, Martin BR, Sim-Selley LJ.

J Neurochem. 2001 May;77(4):1048-57.

3.
4.

Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.

Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM, Martin BR, Abood ME.

Eur J Pharmacol. 1999 Jul 14;377(1):117-25.

PMID:
10448934
5.

An investigation into the structural determinants of cannabinoid receptor ligand efficacy.

Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME.

Br J Pharmacol. 1999 Apr;126(7):1575-84.

6.

Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation.

Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB.

Oncogene. 1997 Sep 4;15(10):1191-7.

Supplemental Content

Loading ...
Support Center